Regeneron Pharmaceuticals (REGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2020 | 12-2019 | 12-2018 | 12-2017 | 12-2016 | |
| Sales | 8,497,100 | 6,557,600 | 5,145,600 | 5,872,200 | 4,860,400 |
| Cost of Goods | 1,119,900 | 765,100 | 417,500 | 397,100 | 299,700 |
| Gross Profit | 7,377,200 | 5,792,500 | 4,728,100 | 5,475,100 | 4,560,700 |
| Operating Expenses | 3,801,500 | 3,582,800 | 2,194,200 | 3,395,600 | 3,230,700 |
| Operating Income | 3,576,600 | 2,209,800 | 2,534,400 | 2,079,600 | 1,330,700 |
| Interest Expense | 56,900 | 30,200 | 28,200 | 25,100 | 7,200 |
| Other Income | 290,700 | 249,500 | 47,300 | 24,000 | 6,300 |
| Pre-tax Income | 3,810,400 | 2,429,100 | 2,553,500 | 2,078,500 | 1,329,800 |
| Income Tax | 297,200 | 313,300 | 109,100 | 880,000 | 434,300 |
| Net Income Continuous | 3,513,200 | 2,115,800 | 2,444,400 | 1,198,500 | 895,500 |
| Net Income | $3,513,200 | $2,115,800 | $2,444,400 | $1,198,500 | $895,500 |
| EPS Basic Total Ops | 32.65 | 19.38 | 22.65 | 11.27 | 8.55 |
| EPS Basic Continuous Ops | 32.65 | 19.38 | 22.65 | 11.27 | 8.55 |
| EPS Diluted Total Ops | 30.52 | 18.46 | 21.29 | 10.34 | 7.70 |
| EPS Diluted Continuous Ops | 30.52 | 18.46 | 21.29 | 10.34 | 7.70 |
| EPS Diluted Before Non-Recurring Items | 28.66 | N/A | N/A | N/A | N/A |
| EBITDA(a) | $3,812,500 | $2,420,100 | $2,682,600 | $2,225,100 | $1,435,400 |